ICMR invites bids from pharma firms for development of vaccine against Monkeypox

Published On 2022-07-28 12:30 GMT   |   Update On 2022-07-28 12:30 GMT

The National Institute of Virology (NIV) in Pune under ICMR has isolated the monkeypox virus from the clinical specimen of a patient which can pave the way for the development of diagnostic kits and vaccines against the disease, the apex health research body said on Wednesday.

With India isolating the virus, the Indian Council of Medical Research (ICMR) also invited expression of interest (EoI), proposing to hand over the strain to interested Indian vaccine manufacturers, pharma companies and in-vitro diagnostic industry partners for the development of indigenous vaccines against monkeypox and diagnostic kits for detection of the disease.

For more details, check out the full story on the link below:

ICMR Invites Bids From Pharma Companies For Development Of Monkeypox Vaccine


Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News